The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Evolving role of CELMoDs in multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the evolving role of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma. He highlights the efficacy and tolerability of mezigdomide across combination strategies, including with standard therapies and immunotherapies, as well as emerging data supporting CELMoDs as an important class of oral therapies in relapsed disease. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think honestly, CELMoDs are the talk of 2026, actually, in fairness. I think with the success of SUCCESSOR-2, if you’ll excuse the dreadful pun, you know, we’re so pleased with how mezi’s performed with results that are essentially comparable in terms of PFS to what we saw with CARTITUDE-3 and even in the same patient population with CARTITUDE-4. So I apologize with KarMMa-3 and KarMMa-4...
I think honestly, CELMoDs are the talk of 2026, actually, in fairness. I think with the success of SUCCESSOR-2, if you’ll excuse the dreadful pun, you know, we’re so pleased with how mezi’s performed with results that are essentially comparable in terms of PFS to what we saw with CARTITUDE-3 and even in the same patient population with CARTITUDE-4. So I apologize with KarMMa-3 and KarMMa-4. So that was striking. Obviously, we’ve got the bispecific data, which is magnificent. I think what essentially we’re seeing is that CELMoDs have a place amongst immunotherapies in terms of benefit in their own right. And I think what we’re seeing is that CELMoDs are floating all boats. In other words, they’re great with standard therapies. They’re great with immunotherapies. And there’s data at this meeting from the Korean group looking at the combination of mezigdomide with bispecific therapy, which is amazing. The data are phenomenal. And that sort of says a lot, I think, about immunotherapy. I think conversely, with standard therapies, the CELMoDs are performing beautifully. And obviously, the EXCALLIBER data presented as a plenary session at this meeting by my colleague, Dr Sagar Lonial. It’s been a privilege to be part of that trial with him and others. We’re seeing this huge MRD benefit, much greater than we expected. We’re seeing a presumed PFS benefit, recognizing the FDA approval, and more data will come on that. I think this is very good news for patients. Well-tolerated, powerful oral agents, different from immunomodulators. They are distinct, and they combine very well with antibodies, proteasome inhibitors, and, of course, with immunotherapy. So I think from a patient perspective, great news. Oral therapy works when other treatments have failed. And at the end of the day, it’s well tolerated. They are well tolerated. So we’re very excited about CELMoDs. I think in my humble opinion, a major contribution.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
